The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab-Reference-Cited by-同舟云学术

The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab

Published:2015-11-16 Issue:3 Volume:172 Page:428-438
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Forero-Castro Maribel¹²,Robledo Cristina¹,Lumbreras Eva¹,Benito Rocio¹,Hernández-Sánchez Jesús M.¹,Hernández-Sánchez María¹,García Juan L.³,Corchete-Sánchez Luis A.⁴,Tormo Mar⁵,Barba Pere⁶,Menárguez Javier⁷,Ribera Jordi⁸,Grande Carlos⁹,Escoda Lourdes¹⁰,Olivier Carmen¹¹,Carrillo Estrella¹²,García de Coca Alfonso¹³,Ribera Josep-María⁸,Hernández-Rivas Jesús M.¹⁴

Affiliation:

1. Cancer Research Centre; IBSAL; IBMCC; University of Salamanca; CSIC; Salamanca Spain

2. School of Biological Sciences (GEBIMOL); Pedagogical and Technological University of Colombia (UPTC); Colombia IN USA

3. Studies Institute of Health Sciences of Castilla and León (IESCYL); Salamanca Spain

4. Haematology Department; University Hospital of Salamanca; Salamanca Spain

5. Haematology Department; Clinical University Hospital of Valencia; Valencia Spain

6. Haematology Department; Vall d'Hebron Hospital; Barcelona Spain

7. Pathology Department; Gregorio Marañón Hospital; Madrid Spain

8. Clinical Haematology Department ICO-Hospital Germans Trias i Pujol; Jose Carreras Research Institute; Badalona Spain

9. Haematology Department; University Hospital October 12; Madrid Spain

10. Haematology Department; University Hospital of Tarragona Joan XXIII; Tarragona Spain

11. Haematology Department; General Hospital of Segovia; Segovia Spain

12. Haematology Department; University Hospital Virgen del Rocío; Seville Spain

13. Haematology Department; Clinical University Hospital of Valladolid; Valladolid Spain

Funder

Seventh Framework Programme

Fundación-Castellano-Leonesa de Hematología-y-Hemoterapia (FUCALHH 2013)

Consejería de Educación, Junta de Castilla y León (HUS272U13)

SACYL

Fondo de Investigaciones Sanitarias

COST-Action-EuGESMA

Fundación Española de Hematología y Hemoterapia

Red Temática de Investigación Cooperativa en Cáncer

Instituto de Salud Carlos III

Spanish Ministry of Economy and Competitiveness

European Regional Development Fund

UPTC

MHS

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13849/fullpdf

Reference51 articles.

1. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements;Bain;Cell,1994

2. Homogeneous immunophenotype and paucity of secondary genomic aberrations are distinctive features of endemic but not of sporadic Burkitt's lymphoma and diffuse large B-cell lymphoma with MYC rearrangement;Barth;The Journal of Pathology,2004

3. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report;Barth;British Journal of Haematology,2013

4. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach;Bellan;Hematological Oncology,2010

5. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge;Boerma;Leukemia,2009

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia;Annals of Hematology;2024-03-07

2. Diagnosis and Treatment of Burkitt Lymphoma in Adults: Clinical Practice Guidelines from ERN-EuroBloodNet "Recommendations Carried Out within the Framework of European Reference Network on Rare Haematological Diseases (ERN-EuroBloodNet)-Project ID No 10108571. ERN-EuroBloodNet is Partly Co-Funded by the European Union within the Framework of the Fourth EU Health Programme";2024

3. Burkitt lymphoma;Nature Reviews Disease Primers;2022-12-15

4. Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age;Nature Communications;2022-07-06

5. Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on BCR-ABL1-like subtype;Acta Oncologica;2021-03-22